door Electrostatically sure lanreotide peptide – gold nanoparticle conjugates for enhanced uptake in SSTR2-positive most cancers cells
Lanreotide peptide (LP) has excessive affinity to somatostatin receptors like SSTR2 and is often used within the remedy of neuro-endocrine tumors. The primary goal of this research is to focus on gold nanoparticles (AuNPs) in direction of SSTR2-positive most cancers cells utilizing lanreotide peptide (LP) because the concentrating on agent for enhanced tumor uptake and antitumor exercise. pH mediated adjustments within the floor potential of LP and AuNP is used to put together electrostatically sure AuNP-LP complexes.
AuNP-LP complicated formation was demonstrated by UV-Seen spectroscopy, floor potential, dynamic gentle scattering (DLS), small angle X-ray scattering and HR-TEM. Confocal microscopy and move cytometric research present that AuNP-LP complicated has greater mobile uptake in SSTR2 expressed most cancers cells (MCF-7 and AR42J) than in CHO cells. The improved mobile uptake of LP coated AuNPs result in ~1.5 to 2-fold GSH depletion and enhanced ROS technology in MCF-7 cells.
The preferential cytotoxicity of the AuNP-LP complicated in direction of MCF-7 and AR42J cells, as revealed by MTT assay, is in line with the elevated mobile uptake. Our research display that LP coated AuNP can be utilized as an efficient platform to selectively goal SSTR2 optimistic most cancers cells for mixture remedy approaches involving gold nanoparticles.
AAP73769-100UG - BICD1 Peptide - N-terminal region |
|||
| AAP73769-100UG | Aviva Systems Biology | 100ug | EUR 99 |
BICD2 Peptide |
|||
| 4675P | ProSci | 0.05 mg | EUR 197.7 |
|
Description: (CT) BICD2 peptide |
|||
BICD2 Peptide |
|||
| 4677P | ProSci | 0.05 mg | EUR 197.7 |
|
Description: (IN) BICD2 peptide |
|||
BICD2 Peptide |
|||
| MBS152448-005mg | MyBiosource | 0.05mg | EUR 175 |
BICD2 Peptide |
|||
| MBS152448-5x005mg | MyBiosource | 5x0.05mg | EUR 770 |
BICD2 Peptide |
|||
| MBS152730-005mg | MyBiosource | 0.05mg | EUR 175 |
BICD2 Peptide |
|||
| MBS152730-5x005mg | MyBiosource | 5x0.05mg | EUR 770 |
Mast Cell-Degranulating Peptide (MCD Peptide) / Peptide 401 |
|||
| 004-04 | PHOENIX PEPTIDE | 100 μg | EUR 140.4 |
BICD2 Peptide - middle region |
|||
| MBS3244293-01mg | MyBiosource | 0.1mg | EUR 180 |
BICD2 Peptide - middle region |
|||
| MBS3244293-5x01mg | MyBiosource | 5x0.1mg | EUR 730 |
Peptide T |
|||
| 057-01 | PHOENIX PEPTIDE | 5 mg | EUR 140.4 |
FGL Peptide |
|||
| 073-36 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
APK peptide |
|||
| 076-81 | PHOENIX PEPTIDE | 200 μg | EUR 199.8 |
NEF peptide |
|||
| 076-83 | PHOENIX PEPTIDE | 500 μg | EUR 140.4 |
SHA peptide |
|||
| 076-84 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
YSY peptide |
|||
| 076-86 | PHOENIX PEPTIDE | 100 μg | EUR 230.04 |
Peptide E / 3200-Dalton Adrenal Enkephalin-Containing Peptide (Bovine) |
|||
| 024-57 | PHOENIX PEPTIDE | 200 μg | EUR 86.4 |
PSTAIR Peptide |
|||
| 070-61 | PHOENIX PEPTIDE | 500 μg | EUR 129.6 |
PGMtide Peptide |
|||
| 040-69 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
Adjuvant Peptide |
|||
| 070-05 | PHOENIX PEPTIDE | 500 μg | EUR 36.72 |
Peptide-epsilon |
|||
| 058-22 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
Delicious Peptide |
|||
| 070-21 | PHOENIX PEPTIDE | 5 mg | EUR 160.92 |
proSex peptide (20-55) |
|||
| 040-30 | PHOENIX PEPTIDE | 100 μg | EUR 355.32 |
proSex peptide (28-55) |
|||
| 040-31 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
proSex peptide (40-55) |
|||
| 040-32 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Bombinin-Like Peptide 1 amide / prepro-Bombinin-Like Peptide (44-70) amide / prepro-Bombinin-Like Peptide (107-133) amide |
|||
| 007-60 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Peptide F-9 |
|||
| 038-06 | PHOENIX PEPTIDE | 200 μg | EUR 58.32 |
Sturgeon Peptide (137-158) |
|||
| 021-94 | PHOENIX PEPTIDE | 100 μg | EUR 177.12 |
Peptide Lv (Rat) |
|||
| 008-73 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
NGR Peptide 1 |
|||
| 025-74 | PHOENIX PEPTIDE | 200 μg | EUR 184.68 |
Anorexigenic Peptide |
|||
| 070-10 | PHOENIX PEPTIDE | 5 mg | EUR 86.4 |
GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human) |
|||
| 029-03 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human) |
|||
| 029-04 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human) |
|||
| 029-05 | PHOENIX PEPTIDE | 20 μg | EUR 267.84 |
GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human) |
|||
| 029-06 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
Bid BH3 peptide |
|||
| 025-87 | PHOENIX PEPTIDE | 1 mg | EUR 170.64 |
AF-16 Peptide |
|||
| 033-44 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Peptide Lv (Human) |
|||
| 008-71 | PHOENIX PEPTIDE | 100 μg | EUR 405 |
Peptide Lv (Mouse) |
|||
| 008-72 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
GnRH Associated Peptide (GAP) (1-13) / Gn-RH Precursor Peptide (14-26) (Rat) |
|||
| 029-08 | PHOENIX PEPTIDE | 200 μg | EUR 64.8 |
ExE peptide M3mP6 |
|||
| 064-33 | PHOENIX PEPTIDE | 200 μg | EUR 244.08 |
Peptide B (Bovine) |
|||
| 024-56 | PHOENIX PEPTIDE | 200 μg | EUR 81 |
Peptide F (Bovine) |
|||
| 024-58 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
PLP Peptide (103-116) (Bovine) |
|||
| 070-14 | PHOENIX PEPTIDE | 5 mg | EUR 140.4 |
FMRF-Like Peptide |
|||
| 047-32 | PHOENIX PEPTIDE | 1 mg | EUR 27 |
Joining Peptide (Rat) |
|||
| 047-91 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Growth Hormone-Releasing Peptide-Related Peptide-1 (fGRP-RP-1) (Frog) |
|||
| 048-80 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Growth Hormone-Releasing Peptide-Related Peptide-2 (fGRP-RP-2) (Frog) |
|||
| 048-81 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Growth Hormone-Releasing Peptide-Related Peptide-3 (fGRP-RP-3) (Frog) |
|||
| 048-82 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Peptide T (4-8) |
|||
| 057-04 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Peptide T (5-8) |
|||
| 057-05 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Vasonatrin Peptide (VNP) |
|||
| 005-47 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Opioid Peptide Library |
|||
| L-002 | PHOENIX PEPTIDE | 58 peptides | EUR 2691.36 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) |
|||
| 064-01 | PHOENIX PEPTIDE | 200 μg | EUR 108 |
PGMtide Control Peptide |
|||
| 040-70 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
Growth Blocking Peptide |
|||
| 046-92 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
Neuron Specific Peptide |
|||
| 047-55 | PHOENIX PEPTIDE | 200 μg | EUR 140.4 |
Heparin Binding Peptide |
|||
| 025-47 | PHOENIX PEPTIDE | 500 μg | EUR 102.6 |
Gastrin Related Peptide |
|||
| 027-09 | PHOENIX PEPTIDE | 5 mg | EUR 73.44 |
Obesity Peptide Library |
|||
| L-003 | PHOENIX PEPTIDE | 160 peptides | EUR 7267.32 |
[D-Ala1]-Peptide T |
|||
| 057-02 | PHOENIX PEPTIDE | 5 mg | EUR 282.96 |
Peptide YY (PYY) (Human) |
|||
| 059-01 | PHOENIX PEPTIDE | 200 μg | EUR 119.88 |
Eledoisin Related Peptide |
|||
| 046-04 | PHOENIX PEPTIDE | 5 mg | EUR 58.32 |
proSex peptide (28-55) - EIA Kit |
|||
| EK-040-31 | PHOENIX PEPTIDE | 96 wells | EUR 603.72 |
Peptide F 1 (Lobster) |
|||
| 047-62 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
Morphine Tolerance Peptide |
|||
| 050-13 | PHOENIX PEPTIDE | 1 mg | EUR 102.6 |
Phosphate Acceptor Peptide |
|||
| 058-24 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) |
|||
| 064-07 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia brasiliana) |
|||
| 047-39 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia brasiliana) |
|||
| 047-40 | PHOENIX PEPTIDE | 500 μg | EUR 214.92 |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia californica) |
|||
| 047-42 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia californica) |
|||
| 047-43 | PHOENIX PEPTIDE | 500 μg | EUR 214.92 |
FGL Peptide - FAM Labeled |
|||
| FG-073-36A | PHOENIX PEPTIDE | 1 nmol | EUR 405 |
FGL Peptide - Cy3 Labeled |
|||
| FC3-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 672.84 |
FGL Peptide - Cy5 Labeled |
|||
| FC5-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 756 |
Pedal Peptide (Pep) (Aplysia) |
|||
| 047-61 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
ExE peptide M3mP6 mutant |
|||
| 064-35 | PHOENIX PEPTIDE | 200ug | EUR 234.36 |
ExE peptide M3mP6 mutant |
|||
| 064-37 | PHOENIX PEPTIDE | 200ug | EUR 234.36 |
FGL Peptide - FITC Labeled |
|||
| FG-073-36B | PHOENIX PEPTIDE | 1 nmol | EUR 405 |
AF-16 Peptide - Antibody |
|||
| H-033-44 | PHOENIX PEPTIDE | 100 μl | EUR 336.96 |
Artificial peptide SVVYGLR upregulates cell motility and facilitates oral mucosal wound therapeutic
Osteopontin-derived SVVYGLR (SV) 7-amino-acid sequence is a multifunctional and artificial SV peptide implicated in angiogenesis, manufacturing of collagen III, and fibroblast differentiation into myofibroblasts. This research investigated the impact of the SV peptide on mucosal wound therapeutic exercise. Regular human-derived gingival fibroblasts (NHGF) and human oral mucosa keratinocytes (HOMK) had been used for in vitro experiments.
As well as, an oral punch wound was ready on the buccal mucosa in male rats aged 11 weeks, and we evaluated the impact of native injection of SV peptide on wound therapeutic. The artificial SV peptide confirmed no affect on the proliferation and adhesion properties of NHGF and HOMK, but it surely enhanced the cell motility and migration actions. TGF-β1 receptor inhibitor, SB431542 or SB505124, considerably suppressed the SV peptide-induced migration exercise, suggesting an involvement of TGF-β1 receptor activation. Moreover, SV peptide accelerated the therapeutic technique of an in vivo oral wound mannequin, in contrast with management teams.
Additional immunohistological staining of wound tissue revealed that a rise in capillary development and the better variety of fibroblasts and myofibroblasts that migrated into the wound space may contribute to the facilitation of the therapeutic course of produced by the SV peptide. The SV peptide has useful results on oral wound therapeutic via enhancement of the sooner section consisting of angiogenesis and reworking with granulation tissue. The artificial SV peptide could be a helpful remedy possibility, notably for intractable mucosal wounds brought on by trauma or surgical procedure for progressive lesions comparable to oral most cancers.
Characterization and Quantitative Willpower of a Various Group of Bacillus subtilis subsp. subtilis NCIB 3610 Antibacterial Peptides
5 antibacterial peptides produced by Bacillus subtilis NCIB 3610 had been purified, quantified, characterised, and recognized within the current research. Cell-free extracts had been subjected to 3 purification protocols using ammonium sulfate or natural solvent precipitation and their mixture, adopted by ion-exchange chromatography, solid-phase extraction, and preparative high-performance liquid chromatography (HPLC).
The mixed ammonium sulfate and natural solvent precipitation extraction protocol introduced one of the best outcomes for peptide purification. Within the 5 fractions that introduced antimicrobial exercise, antibacterial peptides had been quantified by the turbidometric technique and by HPLC utilizing nisin for exterior calibration, with the second offering extra correct outcomes. All peptides had been pH- and temperature-resistant and their sensitivity to proteases remedy indicated their proteinic nature.
The 5 peptides had been subjected to microwave-assisted acid hydrolysis (MAAH) and following derivatization had been analyzed utilizing norleucine as the inner commonplace, to find out their amino acid content material. The identification of the remoted peptides utilizing the UniProt and PubChem databases indicated that the 4 peptides correspond to UniProt entries of the bacteriocins Subtilosin-A (Q1W152) Subtilosin-SbOX (H6D9P4), Ericin B (Q93GH3), Subtilin (P10946), and the fifth to the non-ribosomal antibacterial lipopeptide surfactin (CID:443592).
The amino acid content material willpower and computational analyses, utilized within the current work on the antimicrobial peptides of B. subtilis, proved an environment friendly screening and quantification technique of bacteriocins that might doubtlessly be utilized in different bacterial strains. The constructed phylogenetic bushes heterogeneity noticed throughout the 5 peptides investigated could be indicative of aggressive benefit of the pressure.
Protein INCA1 (INCA1) Antibody |
|||
| abx029854-80l | Abbexa | 80 µl | EUR 250 |
Protein INCA1 (INCA1) Antibody |
|||
| abx306704-100g | Abbexa | 100 µg | EUR 362.5 |
Protein INCA1 (INCA1) Antibody |
|||
| 20-abx306704 | Abbexa |
|
|
Protein INCA1 (INCA1) Antibody |
|||
| abx306704-20g | Abbexa | 20 µg | EUR 162.5 |
Protein INCA1 (INCA1) Antibody |
|||
| abx306704-50g | Abbexa | 50 µg | EUR 250 |
Peptide T |
|||
| 057-01 | PHOENIX PEPTIDE | 5 mg | EUR 140.4 |
FGL Peptide |
|||
| 073-36 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
APK peptide |
|||
| 076-81 | PHOENIX PEPTIDE | 200 μg | EUR 199.8 |
NEF peptide |
|||
| 076-83 | PHOENIX PEPTIDE | 500 μg | EUR 140.4 |
SHA peptide |
|||
| 076-84 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
YSY peptide |
|||
| 076-86 | PHOENIX PEPTIDE | 100 μg | EUR 230.04 |
INCA Peptide |
|||
| 42-270P | ProSci | 0.1 mg | EUR 405.6 |
|
Description: (CT) INCA Peptide |
|||
Recombinant Human Protein INCA1 (INCA1) |
|||
| MBS1351143-002mgBaculovirus | MyBiosource | 0.02mg(Baculovirus) | EUR 1120 |
Recombinant Human Protein INCA1 (INCA1) |
|||
| MBS1351143-002mgEColi | MyBiosource | 0.02mg(E-Coli) | EUR 745 |
Recombinant Human Protein INCA1 (INCA1) |
|||
| MBS1351143-002mgYeast | MyBiosource | 0.02mg(Yeast) | EUR 910 |
Recombinant Human Protein INCA1 (INCA1) |
|||
| MBS1351143-01mgEColi | MyBiosource | 0.1mg(E-Coli) | EUR 895 |
Recombinant Human Protein INCA1 (INCA1) |
|||
| MBS1351143-01mgYeast | MyBiosource | 0.1mg(Yeast) | EUR 1065 |
Recombinant Mouse Protein INCA1 (Inca1) |
|||
| MBS1342408-002mgBaculovirus | MyBiosource | 0.02mg(Baculovirus) | EUR 1125 |
Recombinant Mouse Protein INCA1 (Inca1) |
|||
| MBS1342408-002mgEColi | MyBiosource | 0.02mg(E-Coli) | EUR 740 |
Recombinant Mouse Protein INCA1 (Inca1) |
|||
| MBS1342408-002mgYeast | MyBiosource | 0.02mg(Yeast) | EUR 905 |
Recombinant Mouse Protein INCA1 (Inca1) |
|||
| MBS1342408-01mgEColi | MyBiosource | 0.1mg(E-Coli) | EUR 885 |
Recombinant Mouse Protein INCA1 (Inca1) |
|||
| MBS1342408-01mgYeast | MyBiosource | 0.1mg(Yeast) | EUR 1055 |
INCA1 |
|||
| CSB-CL605764HU | Cusabio | 10 μg plasmid + 200μl Glycerol | Ask for price |
Peptide E / 3200-Dalton Adrenal Enkephalin-Containing Peptide (Bovine) |
|||
| 024-57 | PHOENIX PEPTIDE | 200 μg | EUR 86.4 |
PSTAIR Peptide |
|||
| 070-61 | PHOENIX PEPTIDE | 500 μg | EUR 129.6 |
PGMtide Peptide |
|||
| 040-69 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
Adjuvant Peptide |
|||
| 070-05 | PHOENIX PEPTIDE | 500 μg | EUR 36.72 |
Peptide-epsilon |
|||
| 058-22 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
Delicious Peptide |
|||
| 070-21 | PHOENIX PEPTIDE | 5 mg | EUR 160.92 |
proSex peptide (20-55) |
|||
| 040-30 | PHOENIX PEPTIDE | 100 μg | EUR 355.32 |
proSex peptide (28-55) |
|||
| 040-31 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
proSex peptide (40-55) |
|||
| 040-32 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Bombinin-Like Peptide 1 amide / prepro-Bombinin-Like Peptide (44-70) amide / prepro-Bombinin-Like Peptide (107-133) amide |
|||
| 007-60 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Peptide F-9 |
|||
| 038-06 | PHOENIX PEPTIDE | 200 μg | EUR 58.32 |
Sturgeon Peptide (137-158) |
|||
| 021-94 | PHOENIX PEPTIDE | 100 μg | EUR 177.12 |
Peptide Lv (Rat) |
|||
| 008-73 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
NGR Peptide 1 |
|||
| 025-74 | PHOENIX PEPTIDE | 200 μg | EUR 184.68 |
Anorexigenic Peptide |
|||
| 070-10 | PHOENIX PEPTIDE | 5 mg | EUR 86.4 |
GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human) |
|||
| 029-03 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human) |
|||
| 029-04 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human) |
|||
| 029-05 | PHOENIX PEPTIDE | 20 μg | EUR 267.84 |
GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human) |
|||
| 029-06 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
Bid BH3 peptide |
|||
| 025-87 | PHOENIX PEPTIDE | 1 mg | EUR 170.64 |
AF-16 Peptide |
|||
| 033-44 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Peptide Lv (Human) |
|||
| 008-71 | PHOENIX PEPTIDE | 100 μg | EUR 405 |
Peptide Lv (Mouse) |
|||
| 008-72 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
Human Protein INCA1 (INCA1) ELISA Kit |
|||
| abx528370-96tests | Abbexa | 96 tests | EUR 687.5 |
Mouse Protein INCA1 (INCA1) ELISA Kit |
|||
| abx528371-96tests | Abbexa | 96 tests | EUR 687.5 |
Mouse Protein INCA1, Inca1 ELISA KIT |
|||
| ELI-27217m | Lifescience Market | 96 Tests | EUR 1038 |
Human Protein INCA1, INCA1 ELISA KIT |
|||
| ELI-12532h | Lifescience Market | 96 Tests | EUR 988.8 |
GnRH Associated Peptide (GAP) (1-13) / Gn-RH Precursor Peptide (14-26) (Rat) |
|||
| 029-08 | PHOENIX PEPTIDE | 200 μg | EUR 64.8 |
ExE peptide M3mP6 |
|||
| 064-33 | PHOENIX PEPTIDE | 200 μg | EUR 244.08 |
Peptide B (Bovine) |
|||
| 024-56 | PHOENIX PEPTIDE | 200 μg | EUR 81 |
Peptide F (Bovine) |
|||
| 024-58 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
PLP Peptide (103-116) (Bovine) |
|||
| 070-14 | PHOENIX PEPTIDE | 5 mg | EUR 140.4 |
FMRF-Like Peptide |
|||
| 047-32 | PHOENIX PEPTIDE | 1 mg | EUR 27 |
Joining Peptide (Rat) |
|||
| 047-91 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Growth Hormone-Releasing Peptide-Related Peptide-1 (fGRP-RP-1) (Frog) |
|||
| 048-80 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Growth Hormone-Releasing Peptide-Related Peptide-2 (fGRP-RP-2) (Frog) |
|||
| 048-81 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Growth Hormone-Releasing Peptide-Related Peptide-3 (fGRP-RP-3) (Frog) |
|||
| 048-82 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Peptide T (4-8) |
|||
| 057-04 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Peptide T (5-8) |
|||
| 057-05 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Vasonatrin Peptide (VNP) |
|||
| 005-47 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Opioid Peptide Library |
|||
| L-002 | PHOENIX PEPTIDE | 58 peptides | EUR 2691.36 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) |
|||
| 064-01 | PHOENIX PEPTIDE | 200 μg | EUR 108 |
PGMtide Control Peptide |
|||
| 040-70 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
Growth Blocking Peptide |
|||
| 046-92 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
Neuron Specific Peptide |
|||
| 047-55 | PHOENIX PEPTIDE | 200 μg | EUR 140.4 |
Heparin Binding Peptide |
|||
| 025-47 | PHOENIX PEPTIDE | 500 μg | EUR 102.6 |
Gastrin Related Peptide |
|||
| 027-09 | PHOENIX PEPTIDE | 5 mg | EUR 73.44 |
Obesity Peptide Library |
|||
| L-003 | PHOENIX PEPTIDE | 160 peptides | EUR 7267.32 |
[D-Ala1]-Peptide T |
|||
| 057-02 | PHOENIX PEPTIDE | 5 mg | EUR 282.96 |
Peptide YY (PYY) (Human) |
|||
| 059-01 | PHOENIX PEPTIDE | 200 μg | EUR 119.88 |
Eledoisin Related Peptide |
|||
| 046-04 | PHOENIX PEPTIDE | 5 mg | EUR 58.32 |
proSex peptide (28-55) - EIA Kit |
|||
| EK-040-31 | PHOENIX PEPTIDE | 96 wells | EUR 603.72 |
Peptide F 1 (Lobster) |
|||
| 047-62 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
Morphine Tolerance Peptide |
|||
| 050-13 | PHOENIX PEPTIDE | 1 mg | EUR 102.6 |
Phosphate Acceptor Peptide |
|||
| 058-24 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) |
|||
| 064-07 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia brasiliana) |
|||
| 047-39 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
